We showed that HOXC6 and DLX1, independent prognostic markers of prostate tumors [10], are associated with distinct clusters of tumor-specific enhancers and transcriptomic changes in C42B prostate cancer cells upon knockdown of HOXC6 and DLX1. We also discovered de novo motifs specifically enriched in enhancers linked to ZNF395 in kidney tumors. Here, DLX1 is linked to prostate cancer.